Identification of a New Type 2M von Willebrand Disease Mutation also at Position 1324 of von Willebrand Factor

L. Hilbert; E. Fressinaud; A. S. Ribba; D. Meyer; C. Mazurier; and the INSERM network on molecular abnormalities in von Willebrand disease

doi:10.1055/s-0037-1613060

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(04): 635-640
DOI: 10.1055/s-0037-1613060

Review Article

Schattauer GmbH

Identification of a New Type 2M von Willebrand Disease Mutation also at Position 1324 of von Willebrand Factor

Authors

L. Hilbert

¹LFB, Lille, Le Kremlin Bicêtre, France
E. Fressinaud

²CHU Hôtel Dieu, Nantes, Le Kremlin Bicêtre, France
A. S. Ribba

³INSERM U143, Le Kremlin Bicêtre, France
D. Meyer

³INSERM U143, Le Kremlin Bicêtre, France
C. Mazurier

¹LFB, Lille, Le Kremlin Bicêtre, France

and the INSERM network on molecular abnormalities in von Willebrand disease

Abstract

Summary

Type 2M von Willebrand disease (VWD) refers to variants with decreased platelet-dependent function that is not associated with the loss of high molecular weight (HMW) von Willebrand factor (VWF) multimers. This category includes the so-called “phenotype B” responsible for inexistent ristocetin-induced but normal botrocetin-induced binding of VWF to platelet glycoprotein Ib. The missense mutation G1324S was identified in the first patient reported to display “phenotype B”.

We report here on the identification in four members of a French family of a missense mutation also affecting this glycine residue but changing it into an alanine residue. These individuals are heterozygous for this mutation and two of them display an additional quantitative VWF deficiency resulting from a stop codon at position 2470. After transient transfection in Cos-7 cells, the mutated recombinant protein harbouring the G1324A substitution was shown to exhibit normal multimers and inexistent ristocetin-induced but normal botrocetininduced binding to GPIb, confirming the classification of this new mutation as a type 2M VWD mutation.

Keywords

von Willebrand factor - von Willebrand disease - mutation - recombinant protein - Cos-7 cells

Full Text

References

References
1 Weiss HJ, Sussmann II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977; 60: 390-404.
2 Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
3 Fujimura Y, Titani K, Holland LZ, Russell R, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS. Von Willebrand Factor: a reduced and alkylated 52/48-kDa fragment beginning at amino residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-5.
4 Zucker MB, Kim SV, Mc Pherson J, Grant RA. Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol 1977; 35: 535-49.
5 Read MS, Shermer RW, Brinkhous KM. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci USA 1978; 75: 4514-9.
6 Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor dependent agglutination of platelets. J Biol Chem 1991; 266: 8149-55.
7 Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetinmediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib/IX complex. Biochem 1989; 28: 8317-25.
8 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
9 Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE. Von Willebrand disease type B: A missense mutation selectively abolishes ristocetin-induced von Willebrand binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846-9.
10 Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood 2000; 95: 3796-803.
11 Hillery CA, Mancuso DJ, Sadler JE, Ponder JW, Jozwiak MA, Christopherson PA, Gill JC, Scott JP, Montgomery RR. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-81.
12 Hilbert L, Jenkins PV, Gaucher C, Meriane F, Collins PW, Pasi KJ, Mazurier C. Type 2M VWD resulting from a lysine deletion within a four lysine residues repeat in the A1 loop of von Willebrand factor. Thromb Haemost 2000; 84: 188-94.
13 Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gil JC, Montgomery RR. Type 2M:Milwaukee-1 von Willebrand disease: an inframe deletion in the Cys509-Cys695 loop of von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 1996; 88: 2559-68.
14 Nitu-Whalley I, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
15 Schneppenheim R, Federici AB, Bude U, Castaman G, Drewke E, Krey S, Mannucci PM, Riesen G, Rodeghiero F, Zieger B, Zimmermann R. Von Willebrand disease type 2M “Vicenza” in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 82: 136-40.
16 Mannucci PM, Lombardi R, Castaman G, Dent JA, Lattuada A, Rodeghiero F, Zimmerman TS. Von Willebrand disease “Vicenza” with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71: 65-70.
17 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
18 Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
19 Miller SA. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215-8.
20 Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (VWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of VWF. Blood 1995; 86: 1010-8.
21 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au Facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand. Pathol Biol 1977; 25: 18-24.
22 Ribba AS, Hilbert L, Lavergne JM, Fressinaud E, Boyer-Neumann C, Ternisien C, Juhan-Vague I, Goudemand J, Girma JP, Mazurier C, Meyer D. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. Blood 2000; 97: 952-9.
23 Howard MA, Salem HH, Thomas KB, Hau L, Perkin J, Coghlan M, Firkin BG. Variant von Willebrand’s disease type B. Blood 1982; 60: 1420-8.
24 Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutations sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand’s disease. Blood 1998; 92: 2032-44.
25 Vasudevan S, Roberts JR, McClintock RA, Dent JA, Celikel R, Ware J, Varughese KI, Ruggeri ZM. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibα. J Biol Chem 2000; 275: 12763-8.
26 Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-401.
27 Casana P, Martinez F, Espinos C, Haya S, Lorenzo JI, Aznar JA. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene. New mutations R1315C and R1341W, associated with type 2M and 2B variants. Am J Haematol 1998; 598: 57-63.
28 Lethagen S, Frick K, Isaksson C, Kristoffersson AC, Holmberg L. Revised classification and treatment of von Willebrand disease. Thromb Haemost 1998; 80: 199-200.
29 Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A. Type 2M von Willebrand disease variant characterized by abnormal von Willebrand factor multimerization. J Lab Clin Med 2001; 137: 70-6.
30 Veyradier A, Dakik O, Lavergne JM, Ribba AS, Girma JP, Hilbert L, Mazurier C, Fressinaud E, Meyer D. and the INSERM Network on molecular abnormalities of von Willebrand disease. Von Willebrand disease “Vicenza” with mutation R1205H of von Willebrand factor (VWF): study of 18 French patients and of recombinant VWF. Thromb Haemost. 2001 abstr.